Phytotherapy in Inflammatory Lung Diseases: An Emerging Therapeutic Interventional Approach
- Publication Type:
- Phytochemistry: An in-silico and in-vitro Update, 2019, pp. 331 - 347
- Issue Date:
|Wadhwa2019_Chapter_PhytotherapyInInflammatoryLung.pdf||Published version||412.22 kB|
|Wadhwa2019_Chapter_PhytotherapyInInflammatoryLung.pdf||Published version||412.23 kB|
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Chronic obstructive pulmonary disease (COPD) and asthma are the most common inflammatory respiratory diseases related to an increase in mortality and morbidity. Generally, bronchodilators, ß- agonists, anticholinergics and theophylline used for treatment in these conditions and administered by inhalation for delivery, have localized and systematic effects. The adverse effects are due to pharmacodynamic and pharmacokinetic changes and especially drug-drug and drug-disease interactions. However, phytotherapy is classical and widespread throughout the world for the treatment of ailments. This chapter highlights cellular and molecular mediators involved in COPD and asthma, the shortcomings of current therapies and the emerging need of phytomedicines. Phytomedicine supports respiratory physiology, bronchial action and possesses antioxidants to maintain homeostasis.
Please use this identifier to cite or link to this item: